13-FEB-2025 6:10

MMYEL ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1803-MM, Maintenance, Len vs Len/Dara 1 N 0 Screening 1420 1448 275 144 69 24 0 08/13/2019 328 128
            1448 275 144 69 24 0      
 
    2 Y 1 Lenalidomide   665 123 65 30 9 0 08/13/2019    
        2 Lenalidomide + Daratumumab   654 125 61 28 9 1      
            1319 248 126 58 18 1      
 
    3 Y 3 Stop vs Continue Treatment   233 67 35 15 4 0 08/13/2019    
            233 67 35 15 4 0      
 
  S2005-WM, Prev. Untreated, I/R +/- Venetoclax 1 Y 1 I+R 92 6 6 4 2 0 0 01/05/2022 108 30
        2 I+R+Venetoclax   1 0 0 0 0 0      
        3 V+R   5 5 2 1 0 0      
            12 11 6 3 0 0      
 
  S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D 1 Y 1 VRD-R 510 21 16 11 6 1 0 10/12/2023 217 82
        2 DRD-R   22 17 10 6 2 0      
        3 DRD-DR   20 16 9 3 2 0      
            63 49 30 15 5 0      
 
  S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 1 Y 0 Induction 338 9 9 8 4 1 0 07/01/2024 125 41
            9 9 8 4 1 0      
 
    2 Y 1 Dara-VCD   1 1 1 0 0 0 07/01/2024    
        2 Melphalan + ASCT   2 2 2 2 1 0      
            3 3 3 2 1 0      
 
Yes EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) 0 E Total Registrations   51 7 5 1 1 0 05/27/2021 205 81
            51 7 5 1 1 0      
 
    1 E Total Registrations   37 4 2 0 0 0 05/27/2021    
            37 4 2 0 0 0      
 
    2 E Total Registrations   29 15 7 3 1 0 05/27/2021    
            29 15 7 3 1 0      
 
No EAA173-MYEL, SMM, Rd +/- Daratumumab 0 E Total Registrations   75 17 4 1 0 0 01/08/2020 245 105
            75 17 4 1 0 0      
 
    1 E Total Registrations   37 11 5 2 0 0 01/08/2020    
            37 11 5 2 0 0      
 

13-FEB-2025 6:10

MMYEL Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs
# of
CURR
IRBs
S2005 WM, Prev. Untreated, I/R +/- Venetoclax 2 Crossover 24-Jun-21 108 30
S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 3 Maintenance 01-Dec-23 125 41